Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 1/20 | 0.60 |
| ▸ | NPY2R | P49146 | 1/20 | 0.60 |
| ▸ | NPY4R | P50391 | 1/20 | 0.60 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.60 |
| ▸ | TACR1 | P25103 | 1/20 | 0.59 |
| ▸ | CXCL8 | P10145 | 5/20 | 0.59 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.58 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.58 |
| ▸ | GLP1R | P43220 | 6/20 | 0.57 |
| ▸ | GIPR | P48546 | 6/20 | 0.57 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29440225 | 0.98 | TACR1 (0.59) | NPY1RNPY2RNPY4RNPY5RTACR1 | |
| SCHEMBL29418257 | 0.90 | BACE1 (0.62) | KISS1RGLP1RGIPR | |
| SCHEMBL29949651 | 0.90 | NPY1R (0.67) | NPY1RNPY2RNPY4RNPY5RKISS1R | |
| SCHEMBL30414398 | 0.89 | NTSR2 (0.61) | TACR1CXCL8KISS1RCXCR4 | |
| SCHEMBL31186286 | 0.89 | KISS1R (0.65) | TACR1CXCL8KISS1RCXCR4 | |
| SCHEMBL31005057 | 0.88 | NPY2R (0.59) | NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL31182571 | 0.88 | NPY2R (0.71) | NPY1RNPY2RNPY4RNPY5RCXCR4 | |
| SCHEMBL29450205 | 0.88 | CXCL8 (0.62) | NPY1RNPY2RNPY4RNPY5RCXCL8 | |
| SCHEMBL30598998 | 0.88 | C5AR1 (0.58) | NPY1RNPY2RNPY4RNPY5RCXCL8 | |
| SCHEMBL30507888 | 0.87 | DPP3 (0.57) | TACR1KISS1RCXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066452-A1 | SYNTHETIC AMPHIPATHIC HELICAL PEPTIDES AND TREATMENT METHODS USING SYNTHETIC AMPHIPATHIC HELICAL PEPTIDES | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2025-02-27 | — | — | US | disclosed |
| US-12214076-B2 | Drug delivery vehicles for atherosclerosis nanomedicine | NORTHWESTERN UNIVERSITY (US) | 2025-02-04 | — | — | US | disclosed |
| US-20240366521-A1 | NANOPARTICLES AND METHODS OF USE | QANA THERAPEUTICS INC. | 2024-11-07 | — | — | US | disclosed |
| CN-118141908-A | Lymph targeting tumor nano vaccine and application thereof | 中国药科大学 | 2024-06-07 | — | — | CN | disclosed |
| WO-2023168350-A2 | SYNTHETIC AMPHIPATHIC HELICAL PEPTIDES AND TREATMENT METHODS USING SYNTHETIC AMPHIPATHIC HELICAL PEPTIDES | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366521-A1 | NANOPARTICLES AND METHODS OF USE | CD63, CLTB, CD47 | NPY1R 3296/4885NPY2R 3981/4885NPY4R 4490/4885 |
| US-12214076-B2 | Drug delivery vehicles for atherosclerosis nanomedicine | EPAS1, IAPP, NPPA | NPY1R 517/4885NPY2R 403/4885NPY4R 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.